36 results on '"Licitra, L"'
Search Results
2. SP-015 Current status of immunotherapy in Head and Neck cancer.
3. SP-0613: Will personalised medicine approaches increase therapeutic options for salivary gland cancers?
4. SP-011: Targeted Agents: Cetuximab and Beyond.
5. SP-0587 BIOLOGY AND TARGETING OF HPV
6. TREATMENT APPROACHES OF NON SQUAMOUS CELL SINONASAL MALIGNANCIES
7. Beneficial role of a functional P53 status in locoregionally advanced oropharyngeal carcinoma treated with radiotherapy or radio-chemotherapy
8. New insights in chemotherapy
9. MO-0717 Seasonality of radiotherapy efficacy for head & neck cancer patients: MACH-NC/MARCH meta-analyses.
10. PO-1798: Quality of radiotherapy treatment plans for locally advanced sinonasal tumors in a phase II trial.
11. PD-0545: Validation of a predictive model for salivary dysfunction during chemo-IMRT for head-neck cancer.
12. PD-0543: An externally validated prognostic CT radiomics model for head and neck cancer patients.
13. PH-0043: Age related toxicity and outcome in oropharyngeal and nasoparyngeal cancer patients.
14. EP-1923 Dimensionality reduction of radiomic features using a clustering coherence-based approach.
15. PO-161 Mutational profile of epithelial, non-glandular sinonasal cancers into 2 prospective clinical trials.
16. PO-165 Phase 2 study on axitinib in recurrent/metastatic salivary gland cancer of upper aerodigestive tract.
17. PO-1577: Baseline MRI-radiomics can predict overall survival in non endemic nasopharyngeal cancer patients.
18. PO-0729 Prognostic factors analysis in a cohort of Nasopharyngeal cancer patients with 5-year follow-up.
19. PO-160 Tumor and retropharyngeal nodal GTVs prognostic role in unresectable non-glandular sinonasal cancers.
20. PO-115 Radiomics-based prediction of response to induction chemotherapy in sinonasal cancer.
21. PO-112 Role of microbiota in predicting oral mucositis in head and neck cancer patients treated with IMRT.
22. OC-042 Genomic characterization of oral premalignant lesions to identify high-risk molecular clusters.
23. OC-045: Best practices for supportive care during chemo-radiotherapy in head and neck cancer patients.
24. EP-1696: Can we increase the dose with particle therapy versus IMRT? A dosimetric study for sinonasal cancer.
25. EP-1080: Definitive or adjuvant IMRT for locally advanced sinonasal tumors: outcome and prognostic factors.
26. EP-1078: Nasopharyngeal Carcinoma: prognostic factors analysis in patients treated with IMRT and chemotherapy.
27. EP-1476: Are there any dosimetric predictors of acute toxicity during RT for NPC that can be modulated by genetic risk factors?
28. PO-131: Radiotherapy for Unresectable Sinonasal Cancer: IMRT vs Coplanar and Non-Coplanar VMAT.
29. PO-119: IMRT for Oropharyngeal Carcinoma: Preliminary Results Focusing on the Impact of HPV Status and Risk Categories.
30. OC-039: Surveillance of Head and Neck Cancer (HNC) Patients: Clinical and Radiological Exams or Symptom Driven Follow Up?
31. PO-092: Salivary Cytokine Levels and Mucositis in Head and Neck Cancer Patients Treated with Chemoradiotherapy.
32. PO-113: Activity and Safety of Vinorelbine in Adenoid Cystic Carcinoma: A Single Institution Retrospective Case Series.
33. LOCALLY ADVANCED NASAL CAVITY AND ETHMOID CARCINOMA: INDUCTION CHEMOTHERAPY FOLLOWED BY MULTIMODAL TREATMENT IN A MONOINSTITUTIONAL SERIES OF PATIENTS
34. Relationship between parotid glands dose and salivary toxicity in patients receiving intensity modulated radiation therapy (IMRT) and chemotherapy for nasopharyngeal carcinoma: Preliminary results
35. Optimizing the treatment ofnasopharyngeal cancer: Anupdate of the milan experience including IMRT and chemotherapy intensification
36. Feasibility and activity of docetaxel, cisplatinum and 5-fluorouracil induction chemotherapy followed by concurrent chemo-radiotherapy (including IMRT) in locally advanced undifferentiated nasopharyngeal cancer (LANPC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.